Docetaxel and exisulind in hormone-refractory prostate cancer☆
References (30)
- et al.
Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma
Ann Oncol
(1999) - et al.
Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines
Biochem Pharmacol
(1999) - et al.
Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis
Urology
(1999) - et al.
Cancer statistics, 2001
CA Cancer J Clin
(2001) - et al.
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
J Clin Oncol
(1996) - et al.
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
J Clin Oncol
(1999) Docetaxel (Taxotere) in hormone-refractory prostate cancer: A new addition to the physicians' toolbag
- et al.
Bcl2 is the guardian of microtubule integrity
Cancer Res
(1997) - et al.
Inactivation of bcl-2 by phosphorylation
- et al.
Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
Cancer Res
(1996)
A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2
Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results
Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
J Clin Oncol
(1999)
Sulindac for polyposis of the colon
J Surg Oncol
(1983)
Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
N Engl J Med
(1993)
Cited by (0)
- ☆
Supported in part by Aventis Pharmaceuticals Inc and Cell Pathways, Inc.
- 1
Dr Ryan has received research support and honoraria from Aventis Pharmaceuttcals Inc.
- 2
Dr Vogelzang has served as a consultant to Avenus Pharmaceuticals Inc and Cell Pathways, Inc. Aventis Pharmaceuticals Inc has donated support to the University of Chicago Cancer Research Center, of which Dr Vogelzang is the director.
Copyright © 2001 Published by Elsevier Inc.